# Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

> **NCT03263429** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Colorectal Cancer
- Metastatic Colorectal Cancer
- RAS Wild Type Colorectal Cancer
- Refractory Colorectal Cancer

## Interventions

- **DRUG:** Glutaminase Inhibitor CB-839
- **BIOLOGICAL:** Panitumumab
- **DRUG:** Irinotecan Hydrochloride (phase I only)
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DEVICE:** Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans

## Key facts

- **NCT ID:** NCT03263429
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-12-21
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-08-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263429, "Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03263429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*